1
|
Kibe Y, Ohka F, Aoki K, Yamaguchi J, Motomura K, Ito E, Takeuchi K, Nagata Y, Ito S, Mizutani N, Shiba Y, Maeda S, Nishikawa T, Shimizu H, Saito R. Pediatric-type high-grade gliomas with PDGFRA amplification in adult patients with Li-Fraumeni syndrome: clinical and molecular characterization of three cases. Acta Neuropathol Commun 2024; 12:57. [PMID: 38605367 PMCID: PMC11010357 DOI: 10.1186/s40478-024-01762-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2024] [Accepted: 03/22/2024] [Indexed: 04/13/2024] Open
Abstract
Li-Fraumeni syndrome (LFS) is an autosomal dominant tumor predisposition syndrome caused by heterozygous germline mutations or deletions in the TP53 tumor suppressor gene. Central nervous system tumors, such as choroid plexus tumors, medulloblastomas, and diffuse gliomas, are frequently found in patients with LFS. Although molecular profiles of diffuse gliomas that develop in pediatric patients with LFS have been elucidated, those in adults are limited. Recently, diffuse gliomas have been divided into pediatric- and adult-type gliomas, based on their distinct molecular profiles. In the present study, we investigated the molecular profiles of high-grade gliomas in three adults with LFS. These tumors revealed characteristic histopathological findings of high-grade glioma or glioblastoma and harbored wild-type IDH1/2 according to whole exome sequencing (WES). However, these tumors did not exhibit the key molecular alterations of glioblastoma, IDH-wildtype such as TERT promoter mutation, EGFR amplification, or chromosome 7 gain and 10 loss. Although WES revealed no other characteristic gene mutations or copy number alterations in high-grade gliomas, such as those in histone H3 genes, PDGFRA amplification was found in all three cases together with uniparental disomy of chromosome 17p, where the TP53 gene is located. DNA methylation analyses revealed that all tumors exhibited DNA methylation profiles similar to those of pediatric-type high-grade glioma H3-wildtype and IDH-wildtype (pHGG H3-/IDH-wt), RTK1 subtype. These data suggest that high-grade gliomas developed in adult patients with LFS may be involved in pHGG H3-/IDH-wt. PDGFRA and homozygous alterations in TP53 may play pivotal roles in the development of this type of glioma in adult patients with LFS.
Collapse
Affiliation(s)
- Yuji Kibe
- Department of Neurosurgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| | - Fumiharu Ohka
- Department of Neurosurgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan.
| | - Kosuke Aoki
- Department of Neurosurgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| | - Junya Yamaguchi
- Department of Neurosurgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| | - Kazuya Motomura
- Department of Neurosurgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| | - Eiji Ito
- Department of Neurosurgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| | - Kazuhito Takeuchi
- Department of Neurosurgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| | - Yuichi Nagata
- Department of Neurosurgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| | - Satoshi Ito
- Department of Neurosurgery, Konan Kosei Hospital, 137 Oomatsubara, Takaya-cho, Konan, 483-8703, Japan
| | - Nobuhiko Mizutani
- Department of Neurosurgery, Konan Kosei Hospital, 137 Oomatsubara, Takaya-cho, Konan, 483-8703, Japan
| | - Yoshiki Shiba
- Department of Neurosurgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| | - Sachi Maeda
- Department of Neurosurgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| | - Tomohide Nishikawa
- Department of Neurosurgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| | - Hiroki Shimizu
- Department of Neurosurgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| | - Ryuta Saito
- Department of Neurosurgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| |
Collapse
|
2
|
Tansir G, Rastogi S, Dubasi SK, Chitikela S, Reddy LR, Barwad A, Goyal A. Lessons learnt from the clinico-genomic profiling of families with Li Fraumeni syndrome at a tertiary care centre in North India. Ecancermedicalscience 2023; 17:1550. [PMID: 37377684 PMCID: PMC10292852 DOI: 10.3332/ecancer.2023.1550] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2022] [Indexed: 06/29/2023] Open
Abstract
Li Fraumeni syndrome (LFS) is an inherited cancer predisposition syndrome due to TP53 gene mutation. There is sparse literature on LFS in the Indian population. We conducted a retrospective study of patients diagnosed with LFS and their family members, registered at our Medical Oncology Department between September 2015 and 2022. 9 LFS families consisted of 29 patients diagnosed currently or historically with malignancies including 9 index cases and 20 first or second-degree relatives. Of these 29 patients, 7 (24.1%) patients developed their first malignancy before the age of 18 years, 15 (51.7%) were diagnosed between 18and and 60 years, and 7 (24.1%) were diagnosed at age more than 60 years. A total of 31 cancers occurred among the families, including 2 index cases who had metachronous malignancies. Each family had a median of three cancers (range 2-5); sarcoma (n = 12, 38.7% of total cancers) and breast cancer (n = 6, 19.3% of total cancers) being the commonest malignancies. Germline TP53 mutations were documented among 11 patients with cancers and 6 asymptomatic carriers. Of these nine mutations, the most common types were missense (n = 6, 66.6%) and nonsense (n = 2, 22.2%), and the commonest aberration was replacement of arginine with histidine (n = 4, 44.4%). Eight (88.8%) families met either classical or Chompret's diagnostic criteria and two (22.2%) satisfied both. Two (22.2%) families fit the diagnostic criteria prior to onset of malignancy in the index cases but were untested till the index cases presented to us. Four mutation carriers from three families are undergoing screening as per the Toronto protocol. No new malignancies have been detected so far during the mean surveillance duration of 14 months. The diagnosis of LFS has socio-economic implications for patients and their families. Delay in genetic testing misses out a crucial window wherein asymptomatic carriers could initiate surveillance in a timely fashion. Greater awareness on LFS and genetic testing in Indian patients is warranted for better management of this hereditary condition.
Collapse
Affiliation(s)
- Ghazal Tansir
- Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi 110029, India
| | - Sameer Rastogi
- Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi 110029, India
| | - Sravan Kumar Dubasi
- Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi 110029, India
| | - Sindhu Chitikela
- Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi 110029, India
| | - Lavu Rohit Reddy
- Department of Medical Oncology, Yashoda Hospitals, Hyderabad, Telangana 500024, India
| | - Adarsh Barwad
- Department of Pathology, All India Institute of Medical Sciences, New Delhi 110029, India
| | - Ankur Goyal
- Department of Radiodiagnosis, All India Institute of Medical Sciences, New Delhi 110029, India
| |
Collapse
|
3
|
Chen S, Huang W, Liu Z, Jin M, Li J, Meng L, Li T, Diao Y, Gao H, Hong C, Zheng J, Li F, Zhang Y, Bi D, Teng L, Li X. Identification of nine mutant genes and establishment of three prediction models of organ tropism metastases of non-small cell lung cancer. Cancer Med 2022; 12:3089-3100. [PMID: 36161776 PMCID: PMC9939125 DOI: 10.1002/cam4.5233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2022] [Revised: 08/20/2022] [Accepted: 08/24/2022] [Indexed: 11/08/2022] Open
Abstract
BACKGROUND Most Non-small cell lung cancer (NSCLC) patients tend to have metastases at the initial diagnosis. However, limited knowledge has been established regarding which factors, are associated with its metastases. This study aims to identify more biomarkers associated with its organ tropism metastasis and to establish models for prediction of its metastatic organs. METHODS We performed targeted next-generation sequencing (NGS) to detect genes related to lung cancer in 272 patients with primary advanced NSCLC from Northeast China. We adopted Fisher test, multivariate logistic regression analysis to identify metastasis-related gene mutations and to establish prediction models. RESULTS Mutations of EGFR (p = 0.0003, OR = 2.554) (especially EGFR L858R [p = 0.02, OR = 2.009]), ATM (p = 0.008, OR = 11.032), and JAK2 (p = 0.009, OR = Inf) were positively and of TP53 exon4mut (p = 0.001, OR = 0.173) was negatively correlated with lung metastasis, and those of CSF1R (p = 0.01, OR = Inf), KIT (p = 0.03, OR = 4.746), MYC (p = 0.05, OR = 7.938), and ERBB2 (p = 0.02, OR = 2.666) were positively correlated with pleural dissemination; those of TP53 (p = 0.01, OR = 0.417) was negatively, while of SMAD4 (p = 0.03, OR = 4.957) was positively correlated with brain metastasis of NSCLC. Additionally, smoking history (p = 0.004, OR = 0.004) was negatively correlated with pleural dissemination of NSCLC. Furthermore, models for prediction of lung metastasis (AUC = 0.706), pleural dissemination (AUC = 0.651), and brane metastasis (AUC = 0.629) were established. CONCLUSION Taken together, this study revealed nine mutant genes and smoking history associated with organ tropism metastases of NSCLC and provided three models for the prediction of metastatic organs. This study enables us to predict the organs to which non-small cell lung cancer metastasizes before it does develop.
Collapse
Affiliation(s)
- Shuchen Chen
- Department of Thoracic Medicine, Cancer Hospital of China Medical UniversityLiaoning Cancer Hospital and InstituteShenyangChina
| | - Wanyi Huang
- School and Hospital of StomatologyChina Medical University, Liaoning Provincial Key Laboratory of Oral DiseasesShenyangChina,Department of Aging Science and Pharmacology, Faculty of Dental ScienceKyushu UniversityFukuokaJapan
| | - Zhenzhen Liu
- Department of Thoracic Medicine, Cancer Hospital of China Medical UniversityLiaoning Cancer Hospital and InstituteShenyangChina
| | - Meizi Jin
- Department of Thoracic Medicine, Cancer Hospital of China Medical UniversityLiaoning Cancer Hospital and InstituteShenyangChina
| | - Jielin Li
- Department of Thoracic Medicine, Cancer Hospital of China Medical UniversityLiaoning Cancer Hospital and InstituteShenyangChina
| | - Lihui Meng
- Department of Thoracic Medicine, Cancer Hospital of China Medical UniversityLiaoning Cancer Hospital and InstituteShenyangChina
| | - Ting Li
- Department of Thoracic Medicine, Cancer Hospital of China Medical UniversityLiaoning Cancer Hospital and InstituteShenyangChina
| | - Yuzhu Diao
- Department of Thoracic Medicine, Cancer Hospital of China Medical UniversityLiaoning Cancer Hospital and InstituteShenyangChina
| | - Hong Gao
- Department of Thoracic Medicine, Cancer Hospital of China Medical UniversityLiaoning Cancer Hospital and InstituteShenyangChina
| | - Chengyu Hong
- Department of Thoracic Medicine, Cancer Hospital of China Medical UniversityLiaoning Cancer Hospital and InstituteShenyangChina
| | - Jian Zheng
- Department of Thoracic Medicine, Cancer Hospital of China Medical UniversityLiaoning Cancer Hospital and InstituteShenyangChina
| | - Fei Li
- Department of Thoracic Medicine, Cancer Hospital of China Medical UniversityLiaoning Cancer Hospital and InstituteShenyangChina
| | - Yue Zhang
- Hangzhou Jichenjunchuang Medical Laboratory Co. Ltd.HangzhouChina
| | - Dan Bi
- Hangzhou Jichenjunchuang Medical Laboratory Co. Ltd.HangzhouChina
| | - Lin Teng
- Hangzhou Jichenjunchuang Medical Laboratory Co. Ltd.HangzhouChina
| | - Xiaoling Li
- Department of Thoracic Medicine, Cancer Hospital of China Medical UniversityLiaoning Cancer Hospital and InstituteShenyangChina
| |
Collapse
|